Andere Sprachen Bayer AG

Aktien

BAY001

DE000BAY0017

BAYN

Pharmazeutika

Markt geschlossen - Xetra Andere Börsenplätze 17:37:01 06.03.2026			% 5 Tage	Veränd. 1. Jan.
36,39 ^EUR	-3,67 %		-13,38 %	-1,68 %

06.03.	13 TERMINE, die in der Woche wichtig werden -2- (Donnerstag/Freitag)	DJ
06.03.	13 TERMINE, die in der Woche wichtig werden -1- (Montag - Mittwoch)	DJ

Andere Sprachen

06.03.	Bayer : Transcript Q4 2026 Investor Call 2026-03-04
06.03.	Bayer : Climate Transition and Transformation Plan (bag transition transformation plan march 2026)
06.03.	Mwb Sees 'Better Visibility' for Bayer into 2026; Price Target Up
06.03.	Berenberg: US Supreme Court Ruling 'Still Important' for Bayer's Glyphosate Payouts; Hold Rating Kept
06.03.	In the $7.25 billion Roundup settlement, opting out comes at a price
05.03.	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset
05.03.	Bayer : Impact Report (2025 bayer impact report 2025)
05.03.	I mercati rimbalzano, ma i rischi restano
05.03.	Bayer says new data from phase III program support efficacy and safety across clinical settings for gadoquatrane
05.03.	Morning Meeting: Los mercados rebotan mientras persisten los riesgos
05.03.	Les valeurs à suivre à Paris et en Europe (actualisé)
05.03.	Bayer Wins Preliminary US Court Approval for $7.25 Billion Roundup Cancer Settlement
04.03.	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup
04.03.	Bayer Aktiengesellschaft announces Annual dividend, payable on April 29, 2026
04.03.	Plombé par les litiges en 2025, Bayer espère désormais rebondir
04.03.	Bayer : Missouri court grants preliminary approval of Roundup™ class settlement to resolve current and future claims
04.03.	Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge
04.03.	Germany's DAX Index Blinks Green on Upbeat Private Sector Data; adidas Slides
04.03.	Rebond technique sur les places européennes
04.03.	Bayer: Q4 beat, but FX may play spoilsport to 2026 outlook
04.03.	Bayer Announces FDA Clearance for Expanded Capabilities of MEDRAD MRXperion Magnetic Resonance Injection System
04.03.	When Talk of Talks Moves Markets
04.03.	New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
04.03.	Bayer Net Loss Widens on Weedkiller Litigation Charges -- 2nd Update
04.03.	Bayer : Letter from Norbert Winkeljohann, Chairman of the Supervisory Board, to our shareholders (annual meeting letter winkeljohann 2026 en)